Abstract 893P
Background
A 3-week pre-surgery peri-tumoral/peri-lymphatic administration of a pro-inflammatory cytokine complex biologic (LI) with CIZ (single low dose cyclophosphamide IV, 300 mg/m2), indomethacin (po 25mg tid) and yinc multivitamins (po 15-45mg yinc) + Standard of Care (SOC) to treatment-naïve oral/soft palate (OSP) locally advanced SCC, resulted in CRs/PRs prior to surgery (RECIST 1.0) (pathology confirmed) significantly extend overall survival (OS) in NCCN-defined Lower risk for recurrence (LR) intent to treat (ITT) population vs SOC alone. Joint TN (jTN) stage determined at screening, prior to planned surgery, confirmed at surgery.
Methods
Subjects (923 ITT; 380 [LR], 467 higher-risk) AJCC Stage III/IVa OSP SCC, treatment naïve were randomized 3:1:3 to treatment (Tx) arms LI (+/- CIZ) + SOC or Control (SOC only). LI treated (Tx) received ½ dose 200IU peritumorally + ½ dose daily peri-lymphatically x5/wk for 3 weeks before surgery. Each Tx had comparable (55-56 months median) follow up.
Results
TN data were available at screening and surgery for 815/923 ITT subjects; and 43 pre-surgery responders (R), a general trend of worsening in jTN stage entry to surgery with 6-7% more improved jTN for both LI-Tx vs SOC. Table: 893P
jTN Surgery Outcome Relative to Screening | |||||
Treatment | Worse (W) | Same | Improved (I) | 2-sided p-value (I vs W) | 2-sided p-value vs SOC |
LI+CIZ+SOC | 118 (34.0%) | 134 (38.6%) | 95 (27.4%) | 0.1315 | 0.2781 |
LI+SOC | 40 (34.8%) | 43 (37.4%) | 32 (27.8%) | 0.4096 | 0.4792 |
Combined LI | 158 (34.1%) | 177 (38.3%) | 127 (27.5%) | 0.0754 | 0.2552 |
SOC | 121 (34.2%) | 158 (44.8%) | 74 (21.0%) | 0.00094 | - |
No significant differences at screening for subsequent R vs non-R; significant improvement in jTN stage from screening to surgery for LI R (88% improved); jTN differences (p<0.0001) between LR vs HR allowing differentiation of LR from HR at entry. LI-Tx subjects with jTN (I) had >50% 5-year overall survival (OS), while 5-yr OS was <50% for SOC. LI+CIZ+SOC 5-yrs OS >60% (I vs W) p <0.0001; 5-yr OS 30% (W), 50% (Same); LR LI+CIZ+SOC R 5-yr OS >75%, p <0.0001.
Conclusions
jTN differentiated LR vs HR at entry enabling us to search for LR subjects as ideal for neoadjuvant LI-Tx to extend OS. LI neoadjuvant jTN improvement is highly associated with OS joining pre-surgery response to LI as another surrogate marker for OS.
Clinical trial identification
(IT-MATTERS; NCT01265849).
Editorial acknowledgement
Legal entity responsible for the study
CEL-SCI Corporation.
Funding
CEL-SCI Corporation.
Disclosure
J. Timar: Financial Interests, Institutional, Other: CEL-SCI Corp. P. Lavin: Financial Interests, Personal and Institutional, Officer: CEL-SCI Corp. J. Cipriano: Financial Interests, Personal and Institutional, Officer: CEL-SCI Corp. D. Markovic: Financial Interests, Personal and Institutional, Leadership Role: Ergomed plc. E. Talor: Financial Interests, Personal and Institutional, Officer: CEL-SCI Corp.
Resources from the same session
878P - INHBA is overexpressed in HPV-negative oropharyngeal squamous cell carcinoma and contributes to an aggressive phenotype
Presenter: Simon Laban
Session: Poster session 12
880P - ctHPV16-DNA in Liquid Biopsy: A promising biomarker to monitor disease status in patients with HPV-positive oropharyngeal squamous cell carcinoma
Presenter: Nora Würdemann
Session: Poster session 12
881P - SOTO study: Prospective study to correlate the treatment sensitivity of patient-derived organoids (PDOs) with treatment outcomes in head and neck cancer patients
Presenter: Ifigenia Vasiliadou
Session: Poster session 12
882P - Claudin-1 (CLDN1) expression in head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Stefano Cavalieri
Session: Poster session 12
884P - Prognostic value and immune characteristics of LGALS1 in head and neck squamous cell carcinoma
Presenter: Yanfei Min
Session: Poster session 12
885P - Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in nasopharyngeal carcinoma
Presenter: Dingyi Wang
Session: Poster session 12
887P - Antitumor activity of the radioenhancer NBTXR3 on injected lesions to estimate overall survival: Exploratory analyses from a phase I in cisplatin-ineligible locally advanced HNSCC patients
Presenter: Christophe Le Tourneau
Session: Poster session 12
888P - Phase I study of olaparib combined with loco-regional radiotherapy in patients with head and neck squamous cell carcinoma
Presenter: Marcel Verheij
Session: Poster session 12